Each coated, round, purple tablet contains the following dietary

rigieulents.		
Supplement Facts Serving Size 1 Tablet Servings Per Container 90		
	Amount Per Serving	% Daily Value
L-Methylfolate Calcium*, or 6(S)-5-MTHF-Ca	3 mg	**
Pyridoxal 5' Phosphate	35 mg	99
Methylcobalamin	2 mg	**:

contains less than 1% d-methylfolate

(200 cf. pottle / 500 tablets) (200 cf. pottle / 500 tablets)

(90 ct. bottle / 90 tablets)

ХЯ

STATE

L-Methyl-B6-B12

L-Methyl-B6-B12

Tablets RX NDC† 76439-218-90

(90 ct. bottle / 90 tablets) NDC† 76439-218-50 (500 ct. bottle / 500 tablets)

\*\*Daily Values not established for patients with unique nutritional r who are in need of supplementation as directed by a licensed med practitioner.

Other ingredients: See insert for more information.

DOSAGE AND ADMINISTRATION: One tablet twice daily or as directed by a licensed medical practitioner



NDC<sup>†</sup> 76439-218-90

## .-METHYL-B6-B12



Protect from light and moisture. Dispense in a tight, light-resistant container. nant or nursing a baby, ask a health professio

Store at controlled room temperature 15°-30°C (59°-86°F). [See USP].

KEEP THIS OUT OF REACH OF CHILDREN.

All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

Call your medical practitioner about side effects.

You may report side effects by calling 813-283-1344.

NDC<sup>†</sup> 76439-218-90

† see insert for more information on NDCs.

Manufactured for: Virtus Pharmaceuticals, LLC Tampa, FL 33619 Rev. 1/2012 Ma

Made in U.S.A



## Rx 90 Tablets

NDC<sup>†</sup> 76439-218-90 (90 ct. bottle / 90 tablets) NDC<sup>†</sup> 76439-218-50 (500 ct. bottle / 500 tablets)

> L-Methyl-B6-B12 Tablets

## Rx **Prescription Dietary Supplement**

DESCRIPTION: L-Methyl-B6-B12 is an orally administered prescription dietary supplement specifically formulated for the dietary management of pathents with unique nutritional needs requiring increased folate levels.

L-Methyl-B6-B12 should be administered under the supervision of a licensed medical practitioner.

Each coated, round, purple tablet contains the following dietary ingredients:

Supplement Facts Serving Size: 1 toblet Servings Per Container: 90 (NDC 76439-21890 Size: 1 toblet Servings Per Container: 500 (NDC 76439-21850 Servings Per % Daily Val Pyridoxal 5' Phosphate 35 r

\*contains less than 1% d-methylfolate.

\*\*Daily Values not established for patients with unique nutritional needs who are in need of supplementation as directed by a licensed medical practitioner.

Other ingredients: Dicalcium Phosphate, Microcrystalline Cellulose, FD&C Blue #2, FD&C Red #40, Titanium Dioxide, Modified Cellulose, Croscarmellos Sodium, Stearic Acid, Magesium Stearate, Silicon Dioxide, Polyethylene Glycol and Food Glaze. FOLATE REGULATION: The term "folate" are B vitamins that include

FOLAITE REGULATION. The term loater are organized with include folic acid and any forms of active pteroylglutamates regardless of the reduction state of the molecule. Folates, or vitamin B<sub>9</sub>, are primarily hydrolyzed in the intestinal jejunum and the liver to the active circulating form of folate, I-methylfolate, with an intermediate stable form, 5,10-methylenetetrahydrofolate.

Individuals with genetic polymorphisms for the genes coding methylenetetrahydrofolate reductase (MTHFR) may not be capab utilizing or metabolizing folic acid adequately for the vitamin B<sub>12</sub> dependent methylation cycle. pable of

Folic acid, including reduced forms<sup>‡</sup> such as folinic acid, may obscure pemicious anemia above 0.1 mg doses, and must be administered under the supervision of a licensed medical practitioner.

The 1971, 1972, 1973, 1980, 1984, 2000, and 2010 Federal Register Notices addressed this concern while establishing that increased foldate was proper therapy in megaloblastic anemias specifically where homocysteine levels were elevated or risk of neural tube defects (NTDs) was at issue. The Federal Register Notice of August 2, 1973 (38 FR 20750) specifically states that:

Dietary supplement preparations are available without a prescription (21 CFR 121.1134). Levels higher than dietary supplement amounts are available only with a prescription.

\*It is not known whether or not I-methylfolate can obscure pernicious anemia above 0.1 mg doses, so caution is advised also with this form of folate.

Folic acid - including reduced forms, may be added to medical foods as defined in section 5(b)(3) of the Orphan Drug Act (21 USC 360ee(b)(3)), or to food (21 CFR 172.345).

INDICATIONS AND USAGE: L-Methyl-B6-B12 is indicated for the distinct nutritional requirements of patients in need of dietary supplementation as determined by a licensed medical practitioner. L-Methyl-B6-B12 should be administered under the supervision of a licensed medical practitioner.

CONTRAINDICATIONS: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

WARNINGS: Caution is recommended in patients with a history of

PRECAUTIONS: General: Folate, when administered as a single agent in doses about 0.1 mg daily, may obscure the detection of vitamin B<sub>12</sub> deficiency (specifically, the administration of folio acid may reverse the hematological manifestations of B<sub>12</sub> deficiency, including pernicious anemia, while not addressing the neurological manifestations. Folate therapy alone is inadequate for treatment of a vitamin B<sub>12</sub> deficiency.

PATIENT INFORMATION: L-Methyl-B6-B12 is a prescription dietary supplement to be used only under licensed medical supervision.

PRUG INTERACTIONS: Drugs which may interact with folate include:
 Antiepileptic drugs (AED): The AED class including, but not limited to, phenytoin, carbamazepine, primidone, valproic acid, fosphenytoin, valproate, phenobarbital and lamotrigine have been shown to impair folate absorption and increase the metabolism of circulating folate.

Additionally exposurement use of folio acid has been associated.

- of circulating folate.

  Additionally, concurrent use of folic acid has been associated with enhanced phenytoin metabolism, lowering the level of the AED in the blood and allowing breakthrough seizures to occur. Caution should be used when prescribing this product among patients who are receiving treatment with phenytoin and other patience when the processing treatment with phenytoin and other patience when the processing treatment with phenytoin and other patience when the processing treatment with phenytoin and other patiences when the processing treatment with phenytoin and other patiences when the processing treatment with phenytoin and other patiences when the processing treatment with phenytoin and other patiences when the processing treatment with the processing treatment the processing treatme anticonvulsants
- Capecitabine: Folinic acid (5-formyltetrahydrofolate) may increase the toxicity of Capecitabine.
   Cholestyramine: Reduces folic acid absorption and reduces access the control of serum folate levels.
- Colestipol: Reduces folic acid absorption and reduces serum folate levels
- Cycloserine: Reduces folic acid absorption and reduces serum folate levels.

- Dihydrofolate Reductase Inhibitors (DHFRI): DHFRIs block the conversion of folic acid to its active forms, and lower plasma and red blood cell folate levels. DHFRIs include aminopterin, methotrexate, pyrimethamie, triamterene, and trimethoprim.
   Fluoxetine: Fluoxetine exerts a noncompetitive inhibition of the

- Fluoxetine: Fluoxetine exerts a noncompetitive inhibition of the 5-methyltetralytoflotate active transport in the intestine. Isotretinoin: Reduced folate levels have occurred in some patients taking isotretinoin.

  L-dopa, triamterene, colchicine, and trimethoprim may decrease plasma folate levels.

  Nonsteroidal Anti-inflammatory Drugs (NSAIDs): NSAIDs have been shown to inhibit some folate dependent enzymes in laboratory experiments. NSAIDs include ibuprofen, naproxen, indomethacin and sulindac.

  Oral Contraceptives: Serum folate levels may be depressed by oral contraceptives. Feduced serum folate levels have been noted after treatment with methylprednisolone.

  Pancreatic Enzymes: Reduced folate levels have occurred in some patients taking pancreatic extracts, such as pancreatin and pancrelipses.

- some patients taxing particeaue extracts, such as particeaur air. particellipase. Petramidine: Peducate folate levels have been seen with prolonged intravenous pentamidine. Pyrimethamine: High levels of folic acid may result in decreased serum levels of pyrimethamine. Smoking and Alcohol: Reduced serum folate levels have been noted. noted.
- noted.

  Sulfasalazine: Inhibits the absorption and metabolism of folic acid.

  Metformin treatment in patients with type 2 diabetes decreases serum folate. Warfarin can produce significant impairment in folate status after
- Warram can proude significant impairment in loade status after a 6-month therapy.
   Folinic acid may enhance the toxicity of fluorouracil.
   Concurrent administration of chloramphenicol and folinic acid in folate-deficient patients may result in antagonism of the haematopoietic response to folate.
- haematopoietic response to folate.

  Caution should be exercised with the concomitant use of folinic
  acid and trimethoprim-sulfamethoxazole for the acute treatment
  of Pneumocystis carinii pneumonia in patients with HIV infection
  as it is associated with increased rates of treatment failure and
  mortality in a placebo controlled study.

- mortality in a placebo controlled study.

  Drugs which may interact with vitamin B<sub>12</sub>:

   Antibiotics, cholestyramine, colchicines, colestipol, metformin, para-aminosalicylic acid, and potassium chloride may decrease the absorption of vitamin B<sub>12</sub>.

   Nitrous oxide can produce a functional vitamin B<sub>12</sub> deficiency.

  Drugs which interact with vitamin B<sub>8</sub>:

   vitamin B<sub>8</sub> should not be given to patients receiving the drug levodopa because the action of levodopa is antagonized by vitamin B<sub>8</sub>. However, vitamin B<sub>8</sub> may be used concurrently in patients receiving a preparation containing both carbidopa and levodopa.

PREGNANCY and NURSING MOTHERS: L-Methyl-B6-B12 is not intended for use as a prenatal/postnatal multivitamin for lactating and non-lactating mothers. This product contains B vitamins in active form. Talk with your medical practitioner before using if pregnant or leathing lactating.

ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parental administration of folic acid, and may possibly occur with other forms of folate. Paresthesia, somnolence, nausea and headaches have been reported with vitamin B<sub>6</sub>. Mild transient diarrhea, polycythemia vera, tiching, transitory exanthema and the feeling of swelling of the entire body have been associated with vitamin B<sub>12</sub>.

DOSAGE AND ADMINISTRATION: One tablet twice daily or as directed by a licensed medical practitioner.

Indicated by a licensed medicial plactionner.

HOW SUPPLIED: L-Methyl-B6-B12 tablets are coated, round, purple tablets debossed with "BP 0.3" on top and a bisect on bottom, and are supplied in bottles of 90 tablets and 500 tablets.

NDC† 76439-218-90 (90 t. bottle / 90 tablets).

NDC† 76439-218-50 (500 ct. bottle / 500 tablets).

This product is a dietary supplement that – due to increased folate levels (AIO 5 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of 8<sub>12</sub> deficiency. As such, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) as required by pedigree reporting requirements.

**STORAGE:** Store at Controlled Room Temperature 15°-30°C (59°-86°F). [See USP]. Protect from light and moisture. Dispense in a tight, light-resistant container.

Call your medical practitioner about side effects. You may report side effects by calling 813-283-1344.

KEEP THIS OUT OF THE REACH OF CHILDREN.

Prescription Dietary Supplement All prescription susing this product shall be pursuant to state statutes as applicable. This is not an Orange Book product.

Manufactured for: Virtus Pharmaceuticals, LLC Tampa, FL 33619 www.virtusRX.com MADE IN USA



Rev. 12/2012